ArticleBiomedical reports2019
Circular RNAs in leukemia.
Article in Biomedical reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- Understanding the roles and regulation patterns of circRNA on its host gene in tumorigenesis and tumor progression.Journal of experimental & clinical cancer research : CR · 2023Review
- Epigenetic modifications in acute myeloid leukemia: The emerging role of circular RNAs (Review).International journal of oncology · 2021Review
- Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance.Molecular cancer · 2020Review
- Role of circular RNA in hematological malignancies.Oncology letters · 2019Review
- Recent Progress on Circular RNA Research in Acute Myeloid Leukemia.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) have been demonstrated to be biomarkers in human cancers. CircRNAs are majorly recognized in the transcript formation of eukaryotic genes. Research has also revealed that circRNAs regulate gene expression at the transcriptional, post-transcriptional, and translational levels. Notably, there have been studies demonstrating that they contribute to the improvement of various diseases, including cancer. In this regard, they have potential applications in the diagnosis and treatment of cancer. In circRNA studies of blood fluids, plasma circRNAs have been identified as biomarkers in human cancers. For instance, the acute myeloid leukemia-associated hsa_circ_0004277 has been reported to be a biomarker in targeted treatments. This links with circRNAs being highly expressed in hematopoietic tissue; in haematopoiesis, the cell states are controlled by the main regulators and the complex circuits of the RNA family. In particular, circRNA serve a role in cellular processes including self-renewal, apoptosis and proliferation. In the current review, the aim was to explain the role of the defined pathogenic circRNAs derived from leukemia fusion genes and of hsa_circ_0004277 in leukemia cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.